Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.39 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675629 | 0.97 | MEN1 (0.44) | MEN1MAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL1415320 | 0.83 | ESR1 (0.38) | MAPTALOX15HTTTDP1CYP3A4 | |
| SCHEMBL5695686 | 0.80 | TYR (0.46) | ALDH1A1MAPK1HTTHIF1AGAA | |
| SCHEMBL5955 | 0.77 | MAPT (0.53) | MEN1MAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL3482829 | 0.75 | ESR1 (0.52) | MEN1MAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL9510147 | 0.75 | PTGS2 (0.39) | CYP3A4TP53NPC1RAB9A | |
| Water SCHEMBL4672027 | 0.75 | MAPT (0.50) | MEN1MAPTKMT2AALDH1A1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL28370828 | 0.75 | MAPT (0.50) | MEN1MAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL8164161 | 0.75 | ESR1 (0.52) | MEN1MAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL7518483 | 0.75 | MEN1 (0.50) | MEN1MAPTKMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| US-20110082280-A1 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules | BRACCO IMAGING S.P.A. (IT) | 2011-04-07 | — | — | US | disclosed |
| US-7893223-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING S.P.A. (IT) | 2011-02-22 | — | — | US | disclosed |
| US-20100069628-A1 | Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy | BRACCO IMAGING S.P.A (IT) | 2010-03-18 | — | — | US | disclosed |
| EP-1904460-A1 | MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY | BRACCO IMAGING S.p.A. (IT) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136564-A9 | MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY | BRACCO IMAGING SPA (IT) | 2008-02-07 | — | — | WO | disclosed |
| WO-2006136564-A1 | MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY | BRACCO IMAGING S.P.A. (IT) | 2006-12-28 | — | — | WO | disclosed |
| US-20060034773-A1 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034773-A1 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | SSTR3, MB, CA13 | ACHE 909/4885ADRB2 1252/4885MEN1 1383/4885 |
| US-20110082280-A1 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules | CD99, CD209, PRMT9 | ACHE 255/4885ADRB2 1140/4885MEN1 1003/4885 |
| US-20100069628-A1 | Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy | CD99, MB, HBZ | ACHE 421/4885ADRB2 1652/4885MEN1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.